Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec;513(Suppl 1):S96-S99.
doi: 10.1134/S1607672923700692. Epub 2024 Feb 9.

Assessing the Efficacy of Anti-Cancer Drugs on Organoid Models Derived from Prostate Cancer

M O Silkina  1 , A V Razumovskaya  2 , S V Nikulin  2   3 , A G Tonevitsky  2 , B Ya Alekseev  3
Affiliations

Assessing the Efficacy of Anti-Cancer Drugs on Organoid Models Derived from Prostate Cancer

M O Silkina et al. Dokl Biochem Biophys. 2023 Dec.

Abstract

It was proven that tumor organoids effectively mirror the phenotypic and genetic traits of the original biomaterial. It was reported that outcomes from drug testing in organoid cultures can accurately represent the clinical response observed in patients. In this study, an organoid culture was derived from biopsy material of prostate cancer (PC). Subsequently, clinical practice drugs, docetaxel and enzalutamide, were tested on this organoid culture. Various techniques for evaluating the efficacy of drugs in vitro were compared. The half-maximal inhibitory concentration of docetaxel was found to be markedly lower compared to that of enzalutamide. However, when tested at clinically relevant concentrations and incubation times, enzalutamide was more effective than docetaxel. Therefore, it is crucial to optimize the testing conditions for drugs on in vitro cultures for their subsequent application in clinical practice.

Keywords: docetaxel; drug test; enzalutamide; organoids; prostate cancer.

PubMed Disclaimer

Similar articles

See all similar articles

References

REFERENCES

    1. Sung, H., Ferlay, J., Siegel, R.L., et al., Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, Ca—Cancer J. Clin., 2021, vol. 71, no. 3, pp. 209–249. - DOI - PubMed
    1. Kaprin, A.D., Starinskii, V.V., and Shakhzadova, A.O., Zlokachestvennye novoobrazovaniya v Rossii v 2021 godu (zabolevaemost' i smertnost') (Malignant Neoplasms in Russia in 2021 (Incidence and Mortality)), Moscow: MNIOI im. P.A. Gertsena—Filial FGBU NMITs Radiologii Minzdrava Rossii, 2022.
    1. Grimaldi, A.M., Salvatore, M., and Cavaliere, C., Diagnostic and prognostic significance of extracellular vesicles in prostate cancer drug resistance: a systematic review of the literature, Prostate Cancer Prostatic Dis., 2023, vol. 26, no. 2, pp. 228–239. - DOI - PubMed
    1. Montero, A., Fossella, F., Hortobagyi, G., et al., Docetaxel for treatment of solid tumours: a systematic review of clinical data, Lancet Oncol., 2005, vol. 6, no. 4, pp. 229–239. - DOI - PubMed
    1. Scott, L.J., Enzalutamide: a review in castration-resistant prostate cancer, Drugs, 2018, vol. 78, no. 18, pp. 1913–1924. - DOI - PubMed

LinkOut - more resources